Abstract
Cancer-related deaths account for more than 8.8 million individuals per year globally. In spite of exhaustive literature about dysregulated signaling pathways in cancer, correlating it to patient survival warrants further understanding. Therefore, it is pertinent to investigate the working principles behind cellular and molecular tools which facilitate in delineating aberrant alterations used for targeting cancer cells. In addition to existing cell biology techniques, immunoblotting, PCR, FACS, ChIP, EMSA, etc. have immensely contributed to decipher altered molecular and metabolic pathways in cancer. Collectively, these have paved a way toward discoveries and inventions on which modern-day diagnostics and therapeutics are based. This chapter summarizes important techniques in molecular biology and the differential characteristics they target, to understand the approaches used to detect, diagnose, and treat cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adan A et al (2017) Flow cytometry: basic principles and applications. Crit Rev Biotechnol 37:163–176
Bass JJ et al (2017) An overview of technical considerations for Western blotting applications to physiological research. Scand J Med Sci Sports 27:4–25. https://doi.org/10.1111/sms.12702
Bisswanger H (2014) Enzyme assays. Perspect Sci 1:41–55
Bustin SA (2005) Quantitative real-time RT-PCR--a perspective. J Mol Endocrinol 3:597–601
Chaube B et al (2015) AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1α-mediated mitochondrial biogenesis. Cell Death Discov 1:15063–15074
Di Lonardo A et al (2015) Cancer: we should not forget the past. J Cancer 6:29–39. https://doi.org/10.7150/jca.10336
Felipe A et al (2017) The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches. Ecancermedicalscience 11: 746. https://doi.org/10.3332/ecancer.2017.746. Published online 2017 Jun 8
Ferlay J et al (2013) Cancer incidence and mortality worldwide: IARC GLOBOCAN 2012 v1.0, Cancer Base no. 11. International Agency for Research on Cancer, Lyon, France
Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683–693. https://doi.org/10.1038/nrc882
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
http://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 31/08/2018 (2018)
Imran A et al (2017) Role of molecular biology in cancer treatment: a review article. Iran J Public Health 46(11):1475–1485
Jensen EC (2012) The basics of western blotting. Anat Rec (Hoboken) 295:369–371. https://doi.org/10.1002/ar.22424
Kumar S et al (2006) Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 11(5):385405. https://doi.org/10.1080/13547500600775011
Li Y (2004) A modified quantitative EMSA and its application in the study of RNA-protein interactions. J Biochem Biophys Methods 60:85–96
Lukong KE (2017) Understanding breast cancer – the long and winding road. BBA Clin 7:64–77. https://doi.org/10.1016/j.bbacli.2017.01.001. eCollection Jun
Manyhart O et al (2016) Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochim Biophys Acta 1866:300–319
Nelson JD (2006) Fast chromatin immunoprecipitation assay. Nucleic Acids Res 34:1–7
Orfao A et al (1995) Flow cytometry in the diagnosis of cancer. Scand J Clin Lab Invest Suppl 221:145–152
Pittman K (1996) Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol (3):297–301
Protein Blotting Guide (2018) Biorad. http://www.biorad.com/webroot/web/pdf/lsr/literature/Bulletin_2895.pdf?source_wt=s180516000008. Accessed 31/08/2018
Russell GJ et al (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23:537–548
Scott AM et al (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12:14
Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54(1):11–29. https://doi.org/10.1016/j.critrevonc.2004.10.011
Todd HL et al. (1884) Fisheries and fishery Industries of the United States: section I, natural history of useful aquatic animals, plates. Government Printing Office, Washington, DC
Tothill et al (2015) Molecular biosensors: promising new tools for early detection of cancer. Nanobiosensors Dis Diagn:1. https://doi.org/10.2147/NDD.S56772
Vogelstein B et al (2004) Cancer genes and the pathways they control. Nat Med 10:789–799
West CML et al (2004) The potential of positron-emission tomography to study anticancer-drug resistance. Nat Rev Cancer 4(6):457–469
Zhan T et al (2018) CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol. pii: S1044-579X(17)30274-2. https://doi.org/10.1016/j.semcancer.2018.04.001,
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ramteke, P., Athavale, D., Bhat, M.K. (2019). Dysregulated Signaling Pathways in Cancer: Approaches and Applications. In: Bose, K., Chaudhari, P. (eds) Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach. Springer, Singapore. https://doi.org/10.1007/978-981-32-9816-3_10
Download citation
DOI: https://doi.org/10.1007/978-981-32-9816-3_10
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9815-6
Online ISBN: 978-981-32-9816-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)